Gilead Sciences gears up for 2008 with promising new drugs

01/23/2008 | Investor's Business Daily

Analysts believe that Gilead Sciences can expect another good year because of its robust pipeline of new drugs and its HIV treatments. FDA approval this year of two drug candidates -- inhaled antibiotic aztreonam lysine for the treatment of cystic fibrosis and HIV drug Viread for the treatment of chronic hepatitis B in adults -- are expected to boost the biopharmaceutical firm's profits.

View Full Article in:

Investor's Business Daily

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Compliance and Ethics Director
Sysmex America, Inc.
Lincolnshire, IL
Director, Site Quality Management
Palm Springs, CA
Compliance Officer-Medical Products
W. L. Gore
Flagstaff, AZ
Project Manager RA - 15000003MD
Santa Clara, CA
Director, Site Quality Management
Minneapolis, MN